Biofrontera closes restructuring, asset deal with $11M investment

Biofrontera Inc. announced the closing of its restructuring and asset purchase agreement with Biofrontera AG, supported by an investment of $11 million led by existing investors.

Rhea-AI Filing Summary

Biofrontera Inc. announced the closing of its restructuring and asset purchase agreement with Biofrontera AG, supported by an investment of $11 million led by existing investors. The company disclosed this update under Regulation FD, indicating it is being furnished rather than filed.

The closing marks completion of the transaction described, with the new capital noted alongside the deal. The press release providing details was issued on October 23, 2025 and is included as Exhibit 99.1.

Insights

Equity capital markets analyst

Deal closed with $11 million investment; terms via press release.

Biofrontera reports the closing of a restructuring and asset purchase agreement with Biofrontera AG, accompanied by an investment of $11 million led by existing investors. The disclosure is provided under Regulation FD, which typically signals informational transparency rather than a solicitation.

While the headline amount is clear, specifics such as consideration mix, balance sheet effects, or integration steps are in the press release (Exhibit 99.1). Actual impact on liquidity and operations will depend on the transaction’s detailed terms and how the funds are deployed.

The company dated the announcement on October 23, 2025. Subsequent filings may provide additional quantitative effects and updated guidance, if any.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Biofrontera (BFRI) announce in its latest 8-K?

Biofrontera reported the closing of its restructuring and asset purchase agreement with Biofrontera AG, supported by an investment of $11 million.

How much funding is associated with Biofrontera’s transaction?

The agreement is backed by an investment of $11 million led by existing investors.

When was the closing and press release announced by BFRI?

The company announced the closing and issued the press release on October 23, 2025.

Is the information considered filed or furnished?

The information is being furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act.

Where can I find more details about BFRI’s transaction?

Further details are in Exhibit 99.1, the press release dated October 23, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/23/2025 - 08:50 AM Learn about SEC filing dates

false 0001858685 0001858685 2025-10-23 2025-10-23 0001858685 BFRI:CommonStockParValue0.001PerShareMember 2025-10-23 2025-10-23 0001858685 BFRI:PreferredStockPurchaseRightsMember 2025-10-23 2025-10-23 0001858685 BFRI:WarrantsToPurchaseCommonStockMember 2025-10-23 2025-10-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 23, 2025

Biofrontera Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40943		47-3765675
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

120 Presidential Way, Suite 330 Woburn, Massachusetts		01801
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 245-1325

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		BFRI		The Nasdaq Stock Market LLC
Preferred Stock Purchase Rights		No		The Nasdaq Stock Market LLC
Warrants to purchase common stock		BFRIW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the “Exchange Act”) (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On October 23, 2025, Biofrontera Inc. issued a press release announcing the closing of its restructuring and asset purchase agreement with Biofrontera AG, backed by an investment of $11 million led by existing investors. The full text of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in Item 7.01 of this Current Report is being furnished and shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

99.1	Press release dated October 23, 2025
104	Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

October 23, 2025 (Date)	Biofrontera Inc. (Registrant)
	/s/ E Fred Leffler, III
	E Fred Leffler, III Chief Financial Officer